A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the preferred dose of H1N1 pandemic influenza vaccine in a pediatric population, aged 6 months to 17 years, based upon assessments of immunogenicity and safety.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A/H1N1 Immunogenicity and Safety in Adults

NCT00959465

Influenza Pandemic Influenza

COMPLETED PHASE1/PHASE2

Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents

NCT01052402

Influenza, Avian

COMPLETED PHASE1/PHASE2

Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine

NCT00950456

Influenza Pandemic Influenza

COMPLETED

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

NCT01776554

Pandemic H5N1 Influenza

COMPLETED PHASE2

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age

NCT00971100

Pandemic Influenza

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza Pandemic Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose A (3.75 µg HA antigen, 0.25 mL)

Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5 µg) of H1N1 pandemic influenza vaccine at a 21-day interval.

Group Type EXPERIMENTAL

H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)

Intervention Type BIOLOGICAL

2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age

Dose B (7.5µg HA antigen, 0.5 mL)

Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5µg) of H1N1 pandemic influenza vaccine at a 21-day interval. A booster vaccination with a licensed seasonal trivalent influenza vaccine for the season 2010/2011 will be administered to at least 30 subjects in each age stratum (who have received Dose B) at 360 days after the first vaccination.

Group Type EXPERIMENTAL

H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)

Intervention Type BIOLOGICAL

2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age

Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011

Intervention Type BIOLOGICAL

Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)

2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age

Intervention Type BIOLOGICAL

Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011

Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Inflexal V

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent provided by subject's parent(s) / legal guardian(s) (according to national law)
* Written assent provided by subject according to age and capacity of understanding
* Subject is 9 to 17 years (Stratum A), 3 to 8 years (Stratum B), 12 to 35 months (Stratum C) or 6 to 11 months of age (Stratum D) at the time of screening
* Subject was born at full term of pregnancy (\>= 37 weeks) with a birth weight \>= 2 kg (Strata C and D) Subject / parent(s) / legal guardian(s) understand(s) the nature of the study and is / are willing to comply with the requirements of the protocol (e.g. return for follow-up visits, completion of the subject diary)
* If female of childbearing potential, subject presents with a negative urine pregnancy test within 24 hours prior to the first vaccination and agrees to employ adequate birth control measures for the duration of the study
* Subject is generally healthy, as determined by the investigator's clinical judgment through collection of medical history and the performance of a physical examination
* Subject is physically and mentally capable of participating in the study

Exclusion Criteria

* Subject has participated in another clinical study involving an investigational drug, biological product or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an investigational drug, biological product or device during the course of this study
* Subject has a history of exposure to A/H1N1/California/07/2009 virus or a history of vaccination with A/H1N1/California/07/2009 antigen or a closely related influenza virus antigen
* Subject has any inherited or acquired immune deficiency
* Subject currently has or has a recent history of significant neurological, cardiovascular or pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder
* Subject has a history of testing positive for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg) or Hepatitis C Virus (HCV). No confirmatory testing for previous infection with these viruses will be conducted as part of this clinical study.
* Subject has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that could be expected to influence immune response. Such treatment includes, but is not limited to systemic or high dose inhaled corticosteroids, radiation treatment, or other immunosuppressive or cytotoxic drugs.
* Subject has a history of severe allergic reactions or anaphylaxis
* Subject has a rash, dermatologic condition or tattoos which might interfere with injection site reaction rating
* Subject has received a blood transfusion or immunoglobulins within 90 days of study entry
* Subject has received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study Subject has functional or surgical asplenia
* Subject has a known or suspected problem with alcohol or drug abuse
* Subject or one of subject's parent(s) / legal guardian(s) is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, siblings, partner/spouse, parents) as well as employees of the investigator or site personnel conducting the study
* Subject is pregnant or lactating

Minimum Eligible Age

6 Months

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes